{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"}],"title":"Stable Disease"},{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"}],"title":"Progressive Disease"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}],"title":"Not available to evaluate"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"3"}],"units":"Participants"}],"description":"CR- negative SIFE and UIFE, disappearance of any soft tissue plasmacytomas, and \\< or = to 5% plasma cells in bone marrow VGPR - either + SIFE and UIFE and - SPEP and UPEP or reduction in serum M-protein \\> or = to 90% and urine m-protein level \\<100mg per 24h PR - if measurable serum an urine m-protein them reduction of serum m-protein by \\>=50% and reduction in 24h urinary m protein by \\>=90% or to \\<200mg per 24h if unmeasurable serum and urine m-protein then \\>= 50% decrease in the difference between involve and uninvolved FLC levels If unmeasurable serum and urine m-protein and serum FLC assay then \\>= 50% reduction in plasma cells, provide baseline bone marrow plasma cell percentage was \\>=30% In addition to the above listed criteria, if present at baseline, a \\>=50% reduction in the size of soft tissue plasmacytomas is also required PD - defined via International Myeloma Working Group uniform response criteria: disease progression SD - not meeting criteria for CR, VGPR, PR or PD","groups":[{"description":"N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles","id":"OG000","title":"Cohort 1: N-803 - IV 1 ug/kg"},{"description":"N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles","id":"OG001","title":"Cohort 2: N-803 - IV 3 ug/kg"},{"description":"N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles","id":"OG002","title":"Cohort 3: N-803 - IV 6 ug/kg"},{"description":"N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles","id":"OG003","title":"Cohort 4: N-803 - IV 10 ug/kg"},{"description":"N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles","id":"OG004","title":"Cohort 5: N-803 - SQ 10 ug/kg"},{"description":"N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles","id":"OG005","title":"Cohort 6: N-803 - SQ 15 ug/kg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Cohort 5: N-803 - SQ 10 ug/kg - one subject only received 2 doses of study drug. This subject is not evaluable for tumor response assessment.\n\nCohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects","reportingStatus":"POSTED","timeFrame":"Starts at Week 11 - 12 and Week 23 - 24","title":"Disease Response Rate of Treated Patients","type":"PRIMARY","unitOfMeasure":"Participants"}